It was expected and baked into the pps. Unless HR can announce news on major new developments or announce his resignation we will probably be trading around present pps.
NKTR is moving in the same direction as the biotech indexes;
We need significant good news to do better than biotech indexes.
" I am thoroughly convinced the job of leading NKTR is well beyond HR's talents."
I have been saying that for the past several years about HR. HR may be ok in running a non science business but he is totally incompetent in running a biotech company. He does not know anything about drugs, the science involved and is terrible in hiring people to cover his deficiencies. Look at all the incompetents he hired to design trials for 181 and other failed drugs. Look at his lack of partnering of 102 with a big drug firm many years ago by telling us the 102 "results were so good we decided to keep it for ourselves." I could go on and on about all the poor decisions he has made while in charge. had he partnered 102 at that time I bet we would have had a cancer drug in the market by now.
The only reason I have been holding NKTR is the proprietary science that it owns as well as some good scientists that work there. I bet many of these scientists hate HR for botching their hard working discoveries in faulty drug trials while as klause sarcastically has said HR had to buy 50 wheelbarrows to haul all the cash that his cronies on the BOD award him every year!
So 10 legs are made in a year at let's say $10,000 per leg proceeds to DDD. That is $100,000 a year to DDD based on my assumption. Reichental is gloating about these mini accomplishments that may sound great for a university science lab but have very little impact on DDD's profitability. Under his watch the PPS has been decimated. it is about time for his cronies whom he has appointed to the Board of Directors to search their conscience and fire this incompetent person.
They do not even have any data or any specific item and are only on a fishing expedition. It won't surprise me if they were paid by a hedge fund so they either could cover their short position or buy shares on the cheap.
As a lifelong democrat, I will vote republican for the first time in my life if she is nominated.
I agree about Turing and its #$%$ Shkreli. However, Clinton stroked all biotechs with the same brush by her irresponsible statements. Her statements, which BTW are wishful thinking on her part, want to reduce exclusivity to 7 years which is going to make companies like VRTX think twice before they enter costly future drug trials.
He pretends he is the father of a CF child, yet hates VRTX--a company that has put just about ALL of its resources to develop improved drugs for CF patients. Any CF parent who truly loves his/her child is lucky that VRTX is doing all it can for their child. I suspect longlivevrtx is a short pretending he has a CF child. He never posted here before and all of a sudden he has multiple posts badmouthing VRTX.
"I have been following Vrtx for 14 years" and you have not had a single post on this board for 14 years until today?
Here is the number of posts by longlivevrtx during the lifetime of Yahoo's VRTX message board--only 5 posts and apparently they started today!
[containing “longlivevrtx”: 5 results]
is any one familiar with patent laws as they apply to Concert pharma's changing one molecule of kalydeco and claiming it is a better drug and implying they could market that drug if it passes phase 3 successfully?
It sounds to me like someone taking an Apple IPhone, make a little modification and try to sell as a better or similar product. VRTX has not addressed the issue of what Concert is doing even though Concert announced a while ago that they were planning to do this.
Any patent lawyers out there who can help us understand the issue involved or has anyone called VRTX to see what they say about Concert's undertaking?
"a different chemical formula, no matter how small the difference"
So what then is stopping very small biotech firms to take another company's drug, modify it by a molecule, test it and if successful get it approved with a fraction of the expenses incurred by the initial drug company?
A lot of time and expense is involved to research and do a preclinical and animal testing before a drug goes through phase I. It seems to me a competitor drug should be materially different from the one that has a patent to be allowed in the market without arrangement with the patent holder.
Does anyone know if a similar situation has happened before?
Actions such as Shkreli's sometimes cause to push someone who is being drastically affected to flip and take a very drastic action. If I were Shkreli I would be worried.
Both Hillary and sanders are going to cause many democrats, including yours truly to vote republican. I cant wait to democratic fund raisers to call me. I have a few choice words for them.